$MANE News

B. Riley Securities Maintains Buy on Veradermics, Raises Price Target to $204

Could This Pill Be a Game Changer for Hair Loss? Veradermics Reports Major Breakthrough

Veradermics’ stock up on male hair loss trial success

Veradermics Soars 10% as Phase 3 Data Show Oral Hair-Loss Pill Could “Transform” Treatment

Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results

Veradermics, Incorporated (MANE) Discusses Positive Top Line Results From Phase III Study 304 of VDPHL01 in Male Pattern Hair Loss Transcript

Veradermics stock surges as hair loss drug meets Phase 3 goals

Could This Pill Be a Game Changer for Hair Loss? Veradermics Reports Major Breakthrough

Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss

Cantor Fitzgerald Reiterates Overweight on Veradermicsto Overweight

Needham Maintains Buy on Veradermics, Raises Price Target to $172

Veradermics' VDPHL01 Meets All Primary And Secondary Endpoints In Phase 3 Study, Demonstrates Significant Hair Count Gains And Favorable Safety Profile

Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

Veradermics: The Momentum Is Building, But Know This Before H2 2026 Readouts

Veradermics, Incorporated (MANE) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript

Veradermics to Present at Upcoming September Investor Conferences

Veradermics (MANE) Stock Looks Overvalued After Its 161% Rally

Is Veradermics (MANE) Still Undervalued After Its 161% Year To Date Run?

Veradermics Q2 EPS $(0.58) Beats $(0.65) Estimate

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress